| TACE plus apatinib plus camrelizumab (n = 80) |
---|---|
Best overall response | |
 Complete response (CR) | 14 (17.5) |
 Partial response (PR) | 33 (41.3) |
 Stable disease (SD) | 18 (22.5) |
 Progressive disease (PD) | 15 (18.7) |
ORR (CR + PR) | 47 (58.8, 47.2–69.6) |
DCR (CR + PR + SD) | 65 (81.2, 71.0–89.1) |